Candid stewardship of one big open question: management engages seriously with a consequential unresolved outcome
The model's full reasoning — Q4 2022 call → NOWe need to determine if management identifies and seriously engages with one consequential operational outcome that is still unresolved. The call discusses several initiatives: Delphi acquisition, order with Google integration, international expansion, enterprise capabilities, Toast Capital, etc. The question asks for a specific undertaking already in motion whose outcome is not yet known, with candid discussion of what's going well and what's not proven, and what they're doing about it. Looking at the transcript, management discusses the Delphi acquisition as a new capability for drive-through. They say it's not material to 2023 P&L but strategically important. They don't go into detail about integration risks or progress. They also discuss international expansion as early and not material. The order with Google integration is mentioned as a new product but not deeply discussed. The most concrete ongoing initiative might be the expansion into QSR and upmarket segments, but that's more of a strategy. The question asks for a specific undertaking with open outcome. The Delphi acquisition is a specific integration/launch. Management says it's not material but strategically important. They don't discuss what's going well or what's not proven. They just announce it. Another candidate: Toast Capital. They discuss it with some detail about underwriting, repayment, and growth. But is it an "undertaking" with an open outcome? It's an ongoing product. They mention it's growing and accretive. They don't frame it as uncertain. The question emphasizes "one consequential operational outcome that is still unresolved" and management must "seriously engage" with it, showing candor and operational specificity. The call seems to be a standard earnings call with routine results and forward-looking statements. There's no specific initiative where management says "this is uncertain, here's what we're doing, here's what could go wrong." They talk about macro uncertainty but not a specific undertaking. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| MMLP | Martin Midstream Partners L.P. | Q2 2024 | 2024-07-18 | B |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| AKBA | Akebia Therapeutics, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DHX | DHI Group, Inc. | Q2 2017 | 2017-07-28 | D |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| FIBK | First Interstate BancSystem, Inc. | Q4 2016 | 2017-01-27 | B+ |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2016 | 2016-11-18 | D |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| SOHO | Sotherly Hotels Inc. | Q3 2016 | 2016-11-08 | D |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
TACT · Q4 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management seriously engaging with the large QSR rollout as a specific, already-in-motion undertaking whose outcome remains open. Bart describes it as an ongoing testing and implementation process that has taken over two years, with the company expecting it to begin rolling out in the second half of 2023 (mid-to end of Q3 through Q4) if testing succeeds. He notes recent new orders coming in during Q1, acknowledges the process has had “starts and stops,” and frames success around whether testing goes right and whether the pipeline continues to convert. Steve adds that the rollout will drive significant FST growth in 2024 2023. This is treated as genuinely uncertain rather than assured, with concrete operational details on current progress (new orders, testing), remaining risks (testing outcome, integration), and actions being taken (staying close to the customer, filling the pipeline).
FLUX · Q2 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management actively engaging with the unresolved outcome of scaling production to fulfill the record $31.4 million backlog while restoring gross margins, a specific undertaking already in motion through lean manufacturing, second-shift ramp (launching this month), Mexico sourcing, design cost reductions, and aggressive supplier negotiations. They describe concrete progress (weekly orders, production throughput improvements, quality initiatives) alongside acknowledged risks (chip and component shortages, delayed price effects, inventory commitments), explain current actions (vendor metrics, alternate suppliers, ERP changes), and outline success factors (higher-margin large-pack mix, reduced overstocking).
UAA · Q3 2017 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion... whose result is...YES The transcript shows management identifying the ERP system implementation (launched July 1) as a specific, already-in-motion operational outcome whose result remains unresolved. They detail concrete progress (system now stable, service levels improving) and current actions (ongoing change management with vendors and workforce, fine-tuning through Q4 into 2018), while openly noting residual impacts on shipments and productivity that will not fully resolve until later in the year. This is framed as a genuine risk to Q4 and full-year results rather than a guaranteed success, with visible operational specificity on what is working and what remains unproven.